MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis

Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.

This trial try to find a new way of refractory hematological malignancies treatment. Aim of this study evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.

Inclusion Criteria:

• Refractory forms of acute leukemia, but in complete remission (CR)
• Second and third remission of acute leukemia
• 2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL)
• relapsed multiple myeloma
• advanced leukemia

Exclusion Criteria:

• ICU
• Mechanical ventilation